G1 is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of cancer. The Company focuses on cyclin-dependent kinases, or CDKs, a family of proteins that plays an important role in the growth and proliferation of cells, and represents a recently validated and promising class of targets for anti-cancer therapeutics.
Type
Public
HQ
Durham, US
Founded
2008
Size (employees)
38 (est)+27%
G1 Therapeutics was founded in 2008 and is headquartered in Durham, US
Report incorrect company information

Key People/Management at G1 Therapeutics

Mark Velleca

Mark Velleca

CEO
Rajesh Malik

Rajesh Malik

Chief Medical Officer
Jay Strum

Jay Strum

Chief Scientific Officer
Greg Mossinghoff

Greg Mossinghoff

Chief Business Officer

G1 Therapeutics Office Locations

G1 Therapeutics has an office in Durham
Durham, US (HQ)
79 T.W. Alexander Dr.
Show all (1)
Report incorrect company information

G1 Therapeutics Financials and Metrics

G1 Therapeutics Financials

Market capitalization (22-Jun-2018)

1.6 b

Closing share price (22-Jun-2018)

48.3
G1 Therapeutics's current market capitalization is $1.6 b.
Show all financial metrics
Report incorrect company information

G1 Therapeutics News and Updates

Report incorrect company information